Clinical Trials Logo

Cancer of the Liver clinical trials

View clinical trials related to Cancer of the Liver.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03753789 Terminated - Liver Cancer Clinical Trials

Ablation Confirmation Study

Start date: November 5, 2019
Phase: N/A
Study type: Interventional

Prospective, single-arm, multicenter study that will generate clinical data using the NEUWAVE MicroWave Ablation System with AC (Ablation Confirmation) software in patients undergoing ablation of a soft tissue liver lesion.

NCT ID: NCT02618447 Terminated - Liver Cancer Clinical Trials

4D Phase Contrast MR: Hypertrophy in Liver Cancer

Start date: August 5, 2014
Phase: N/A
Study type: Interventional

The investigators hypothesize that 4Dimensional Phase Contrast Magnetic Resonance Angiography (4D PC MRA) evaluation of portal venous flow predicts underlying liver function and hypertrophic potential in patients with liver cancer presenting for portal vein embolization (PVE). 4D PC MRA may provide a non-invasive measure of liver function that could help determine which patients could safely and successfully undergo PVE and subsequent resection of tumor. By comparing 4D PC MRA results with invasive catheter measurements the investigators will validate the flow findings. Further regression/correlation analysis with functional measures of the liver (HIDA scans), volumetrics, Doppler flow analysis, histology, and outcomes will help the investigators to determine the ability of 4D PC MRA to predict functional status and hypertrophic potential of the liver prior to PVE and hepatectomy allowing for better patient selection and reduced morbidity/mortality.

NCT ID: NCT00669136 Terminated - Clinical trials for Hepatocellular Carcinoma

Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma

Start date: June 2009
Phase: Phase 1
Study type: Interventional

To evaluate the safety, toxicity and immunological effects of adjuvant administration of an experimental therapy consisting on priming with three intramuscular administrations of a plasmid expressing human AFP (phAFP) together with a plasmid expressing human GM-CSF (phGM-CSF), followed by a single intramuscular boost with an AFP adenoviral vector (AdVhAFP) to patients with locoregionally pre-treated hepatocellular carcinoma (HCC).

NCT ID: NCT00422877 Terminated - Cancer of the Liver Clinical Trials

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver

Start date: January 2007
Phase: Phase 2
Study type: Interventional

To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failure in patients with primary liver cancer being treated with weekly Taxoprexin® Injection. To explore the trough and peak blood levels of Taxoprexin® and paclitaxel in these patients.